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ABSTRACT 
In 2010, 307 Swedish patients received a new kidney through transplantation, and the first of April 
2011, 603 patients were on the kidney transplant waiting list. In Sweden over 8000 patients are 
presently in active uremic care with about half in dialysis and the other half with a functional kidney 
graft. The numbers of patients in need of active uremic care are escalating and so are the costs for renal 
health care, in Sweden as in most of the western world. For patients with end stage renal disease active 
uremic care is the last option for survival since there is no cure or specific treatment for most renal 
diseases. The lack of treatment options often leaves steroids and chemotherapy as the only available 
choices. In order to find more specific treatment and to cure or delay the progress of renal disease we 
need to learn more about the molecular background of these diseases.  
To increase our understanding of the molecular mechanisms behind renal disease we have studied the 
gene expression in both an animal model of the nephrotic syndrome in rat as well as in human material 
in form of renal biopsies and cell cultures. The most common renal diseases all start in the glomerulus, 
the capillary tuft in the nephron where the ultrafiltration of blood takes place, and therefore we have 
focused on gene expression in the glomerulus. 
When investigating the gene expression in glomeruli from healthy kidney donors and from mice we 
found a core cluster of conserved, highly glomerulus-specific genes. Normal function of some of these 
genes in the glomerulus is already known to be of importance to the filtration barrier and mutations in 
certain of them are tightly connected to proteinuria. The discovered core cluster also contained genes 
that so far has not been coupled to renal function and disease, and can therefore be used as a new 
source of kidney glomerular-specific genes and biomarkers. 
By studying gene expression in rats with nephrotic syndrome and in patients with renal disease we 
found that expression of a special family of extracellular matrix proteins, called proteoglycans, was 
changed in renal disease compared to healthy controls. Proteoglycans are multifunctional proteins with 
functions ranging from holding and releasing signal molecules to making up part of the extracellular 
matrix structure. In patients with IgA nephropathy we found that the proteoglycan perlecan had an 
increased gene expression compared to control, and that the gene expression correlated to the 
excretion of protein in the urine and even to the progress rate of the disease. This suggests that 
perlecan could likely be used as a molecular marker for IgA nephropathy and as such help us to further 
understand the progression of the disease. In addition we have developed a unique method of culturing 
cells from patients with renal disease and we believe that this will give us new information about the 
molecular mechanism of this disorder and help us develop more specific and individualized treatment 
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